Waste, Leaks, and Failures in the Biomarker Pipeline
2017/03/08 by John P. A. Ioannidis, John P A Ioannidis, Patrick M. Bossuyt +1 · 26 citations
Mathematics · Medicine · #Statistical Methods in Clinical Trials #GDF15 and Related Biomarkers #Adipokines, Inflammation, and Metabolic Diseases
paper · pdf · doi:10.1373/clinchem.2016.254649
Abstract
BACKGROUND: The large, expanding literature on biomarkers is characterized by almost ubiquitous significant results, with claims about the potential importance, but few of these discovered biomarkers are used in routine clinical care. CONTENT: The pipeline of biomarker development includes several specific stages: discovery, validation, clinical translation, evaluation, implementation (and, in the case of nonutility, deimplementation). Each of these stages can be plagued by problems that cause failures of the overall pipeline. Some problems are nonspecific challenges for all biomedical investigation, while others are specific to the peculiarities of biomarker research. Discovery suffers from poor methods and incomplete and selective reporting. External independent validation is limited. Selection for clinical translation is often shaped by nonrational choices. Evaluation is sparse and the clinical utility of many biomarkers remains unknown. The regulatory environment for biomarkers remains weak and guidelines can reach biased or divergent recommendations. Removing inefficient or even harmful biomarkers that have been entrenched in clinical care can meet with major resistance. SUMMARY: The current biomarker pipeline is too prone to failures. Consideration of clinical needs should become a starting point for the development of biomarkers. Improvements can include the use of more stringent methodology, better reporting, larger collaborative studies, careful external independent validation, preregistration, rigorous systematic reviews and umbrella reviews, pivotal randomized trials, and implementation and deimplementation studies. Incentives should be aligned toward delivering useful biomarkers.
Citations
Cited by
- Recommendations to improve use and reporting of statistics in animal experiments
- Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. [europepmc]
- Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. [europepmc]
- Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. [europepmc]
- Perspective: Limiting Dependence on Nonrandomized Studies and Improving Randomized Trials in Human Nutrition Research: Why and How. [europepmc]
- Practical guide for identifying unmet clinical needs for biomarkers. [europepmc]
- The Possibility of Systematic Research Fraud Targeting Under-Studied Human Genes: Causes, Consequences, and Potential Solutions. [europepmc]
- Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA). [europepmc]
- The Search for Clinically Useful Biomarkers of Complex Disease: A Data Analysis Perspective. [europepmc]
- Mass spectrometry-based proteomic techniques to identify cerebrospinal fluid biomarkers for diagnosing suspected central nervous system infections. A systematic review. [europepmc]
- Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. [europepmc]
- From laboratory to clinic: Translation of extracellular vesicle based cancer biomarkers. [europepmc]
- How to Ease the Pain of Taking a Diagnostic Point of Care Test to the Market: A Framework for Evidence Development. [europepmc]
- Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness. [europepmc]
- Identification of Putative Early Atherosclerosis Biomarkers by Unsupervised Deconvolution of Heterogeneous Vascular Proteomes. [europepmc]
- Prognostic Research in Traumatic Brain Injury: Markers, Modeling, and Methodological Principles. [europepmc]
- Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas. [europepmc]
- Improving Translation by Identifying Evidence for More Human-Relevant Preclinical Strategies. [europepmc]
- DNA methylation markers detected in blood, stool, urine, and tissue in colorectal cancer: a systematic review of paired samples. [europepmc]
- A semi-supervised approach for rapidly creating clinical biomarker phenotypes in the UK Biobank using different primary care EHR and clinical terminology systems. [europepmc]
- Diagnostic circulating biomarkers to detect vision-threatening diabetic retinopathy: Potential screening tool of the future? [europepmc]
- A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies. [europepmc]
- Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests. [europepmc]
- Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects. [europepmc]
- Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal. [europepmc]
- Extracellular Vesicles as Liquid Biopsy Biomarkers across the Cancer Journey: From Early Detection to Recurrence. [europepmc]
Related